Global Healthcare ETF – Currency Hedged
- International shares
Invest in a portfolio of the world's leading healthcare companies
Overview
Fund Objective
DRUG aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.
Benefits of DRUG
-
Healthcare – a global growth opportunity
Ageing populations, rising living standards and ongoing medical advancements are expected to support increasing ongoing demand for healthcare products and services.
-
Simple access to global healthcare giants
Access a diversified portfolio of the world’s leading healthcare companies, such as Johnson & Johnson, Pfizer and Roche, in one trade.
-
Cost-effective
Passive, index-tracking approach means no ‘active manager’ fees, making DRUG a cost-effective investment for those seeking exposure to the global healthcare sector.
There are risks associated with an investment in DRUG, including market risk, international investment risk, healthcare sector risk and concentration risk. Investment value can go up and down. An investment in the Fund should only be considered as a part of a broader portfolio, taking into account your particular circumstances, including your tolerance for risk. For more information on risks and other features of the Fund, please see the Product Disclosure Statement and Target Market Determination, both available on this website.
How to invest
- You can buy or sell units just like you’d buy or sell any share on the ASX.
- Fund requires no minimum investment.
Key facts
Pricing information
| Current price | |
|---|---|
| Last trade* | |
| % Change (prev day) | |
| Bid (delayed) | |
| Offer (delayed) | |
* Data is delayed by at least 20 minutes.
| NAV | |
|---|---|
| NAV/Unit* | $7.74 |
* As at 6 December 2023
Profile
| Net assets* ($A) | $153,206,421 |
|---|---|
| Units outstanding* (#) | 19,791,319 |
| Management fee and cost** (p.a.) | 0.57% |
| Distribution frequency | Semi-annual |
| Distribution reinvestment plan (DRP) | Full or partial participation available |
| Issuer | Betashares Capital Ltd |
| Registry | Link Market Services |
* As at 6 December 2023
**Certain additional costs apply. Please refer to PDS.Trading information
| ASX code | DRUG |
|---|---|
| Bloomberg code | DRUG AU |
| IRESS code | DRUG.AXW |
| iNAV IRESS code | N/A |
| Market makers | Susquehanna Pacific |
Index information
| Index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index |
|---|---|
| Index provider | Nasdaq |
| Index ticker | N/A |
| Bloomberg index ticker | NQXAUHHN Index |
Holdings & allocation
Portfolio holdings
| Name | Weight (%) |
|---|---|
| UNITEDHEALTH GROUP INC | 8.8% |
| ELI LILLY & CO | 8.1% |
| JOHNSON & JOHNSON | 6.2% |
| NOVO NORDISK A/S | 5.4% |
| MERCK & CO INC | 4.3% |
| ABBVIE INC | 4.1% |
| NOVARTIS AG | 3.6% |
| ROCHE HOLDING AG | 3.4% |
| THERMO FISHER SCIENTIFIC INC | 3.3% |
| ASTRAZENECA PLC | 3.2% |
* As at 7 December 2023. Excludes cash
Sector allocation
| Pharmaceuticals | 47.0% |
|---|---|
| Health Care Equipment | 13.7% |
| Managed Health Care | 12.7% |
| Biotechnology | 12.5% |
| Life Sciences Tools & Services | 7.9% |
| Health Care Supplies | 2.7% |
| Health Care Services | 1.7% |
| Health Care Facilities | 0.8% |
| Health Care Technology | 0.5% |
| Other | 0.4% |
* As of 31 October 2023
Country allocation
| United States | 80.1% |
|---|---|
| Denmark | 6.2% |
| Switzerland | 5.2% |
| Britain | 3.3% |
| Japan | 3.0% |
| France | 1.1% |
| Germany | 0.7% |
| Netherlands | 0.5% |
* As of 31 October 2023
Performance
Fund returns after fees (%)
| Fund | Index | |
|---|---|---|
| 1 month | 3.78% | 3.87% |
| 3 months | -2.51% | -2.36% |
| 6 months | 0.82% | 1.08% |
| 1 year | -3.32% | -2.97% |
| 3 year p.a. | 6.17% | 6.59% |
| 5 year p.a. | 6.42% | 6.72% |
| 10 year p.a. | - | 9.53% |
| Since inception | 7.59% | 7.93% |
| Inception date | 4-Aug-16 | - |
* As at 30 November 2023.
Past performance is not an indicator of future performance. Returns are calculated in Australian dollars using net asset value per unit at the start and end of the specified period and do not reflect brokerage or the bid ask spread that investors incur when buying and selling units on the ASX. Returns are after fund management costs, assume reinvestment of any distributions and do not take into account tax paid as an investor in the Fund. Returns for periods longer than one year are annualised. Current performance may be higher or lower than the performance shown.
Chart
Past performance is not indicative of future performance. Please refer to "Fund returns after fees" for additional information regarding performance/return information.
Distributions
Yield information
| Distribution frequency | Semi-Annual |
|---|---|
| 12 mth distribution yield* | 0.4% |
*As at 31 October 2023. Yield is calculated by summing the prior 12-month per unit distributions divided by the closing NAV per unit at the end of the relevant period. Yield will vary and may be lower at time of investment. Past performance is not indicative of future performance.